Drug Profile
Ticagrelor - AstraZeneca
Alternative Names: AR-C-126532; AZD-6140; Brilinta; BriliqueLatest Information Update: 09 Jan 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; The Medicines Company; Uppsala University; Vanderbilt University
- Class Amines; Anti-infectives; Antianaemics; Antibacterials; Antithrombotics; Azoles; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Purine nucleosides; Pyrimidines; Ribonucleosides; Small molecules; Vascular disorder therapies
- Mechanism of Action Platelet ADP receptor antagonists; Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute coronary syndromes
- Registered Cardiovascular disorders; Stroke
- Phase II Abdominal aortic aneurysm; Community-acquired pneumonia; Coronary artery disease
- Discontinued Peripheral arterial disorders; Vaso-occlusive crisis
Most Recent Events
- 09 Jan 2024 No development reported - Preregistration for Cardiovascular disorders (Prevention) in China (PO) (AstraZeneca pipeline; January 2024)
- 09 Jan 2024 No development reported - Preregistration for Cardiovascular disorders (Prevention) in Japan (PO) (AstraZeneca pipeline; January 2024)
- 08 Jan 2024 No development reported - Preregistration for Stroke (Prevention) in China (PO) (AstraZeneca pipeline; January 2024)